Platinum Industries Limited subsidiary Rivadu Lifesciences Private Limited has entered into an exclusive Sale/Purchase Agreement with CAREGEN Co., Ltd. of Korea. The agreement, executed on September 28, 2026, grants Rivadu exclusive rights to market CAREGEN’s health functional food products under the brand name Korglutide within India.

The partnership is structured as an exclusive arrangement for the Indian territory. A key component of the agreement includes prospects for establishing manufacturing facilities in India, signaling a potential shift from pure importation to local production capabilities for this product line.

Agreement specifics and terms

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing clarifies that CAREGEN Co., Ltd. is not related to Platinum Industries’ promoters or promoter group. Consequently, the transaction does not fall under related party transactions, ensuring it is conducted at arm's length without special rights such as director appointments or share subscription privileges for CAREGEN.

Strategic implications

The move by Rivadu Lifesciences to secure exclusive distribution rights for Korglutide positions Platinum Industries to capitalize on the growing demand for health functional foods in the Indian market. The explicit mention of manufacturing prospects suggests a long-term strategic intent to deepen local integration rather than merely acting as a distributor. This development expands the subsidiary's portfolio beyond its existing operations, leveraging international partnerships to introduce specialized nutritional products to domestic consumers.

Platinum Industries Limited held its sixth Annual General Meeting (AGM) on September 24, 2026. The company adopted the audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, alongside reports from the Board of Directors and auditors.

The meeting was conducted via Video Conferencing (VC) and Other Audio-Visual Means (OAVM) in compliance with Ministry of Corporate Affairs and SEBI guidelines. A total of 41 members attended the session, which commenced at 11:00 am and concluded at 11:30 am. Mr. Krishna Dushyant Rana, Chairman cum Managing Director, delivered the address to shareholders, while Chief Financial Officer Mr. Ashok Bothra presented the financial performance.

Board composition and attendance

The following directors were present at the meeting:

Mr. Radhakrishnan Iyer, Non-Executive Independent Director and Chairman of the Audit Committee, was granted leave of absence due to a medical emergency. Key management personnel, including Company Secretary Ms. Bhagyashree Mallawat, and representatives from statutory, internal, and secretarial audit firms also attended.

Resolutions passed

Shareholders transacted both ordinary and special business items. The ordinary resolutions included the adoption of financial statements and the re-appointment of Mr. Anup Singh as director, who retired by rotation under Section 152 of the Companies Act, 2013. The ratification of remuneration for the Cost Auditor for FY27 was also approved.

Special business resolutions focused on inter-corporate transactions with subsidiaries. While most related party transactions were approved, one special resolution was defeated:

• Grant of loan or inter-corporate deposit to Platinum Oleo Chemicals Private Limited, a subsidiary where a director is interested: Passed.
• Grant of loan or inter-corporate deposit to Rivadu Lifesciences Private Limited, a subsidiary where a director is interested: Not Passed.
• Material related party transactions with Platinum Stabilizers Egypt LLC: Passed.
• Material related party transactions with Platinum Oleo Chemicals Private Limited: Passed.

Voting results analysis

The scrutinizer’s report revealed that while promoter group votes were excluded for interested resolutions, public shareholders largely supported the management’s proposals. However, Resolution No. 6 regarding Rivadu Lifesciences failed to meet the requisite majority for a special resolution.

What the numbers show

The rejection of Resolution No. 6 highlights a divergence in shareholder sentiment regarding specific subsidiary exposures. While all other related party transactions received unanimous support from non-interested voters, the proposal to extend loans or inter-corporate deposits to Rivadu Lifesciences faced significant opposition. With 30.23% of valid non-interested votes cast against the resolution, it failed to secure the required three-fourths majority for a special resolution. This indicates that minority shareholders exercised their veto power on this specific financial exposure, despite supporting similar transactions with other subsidiaries like Platinum Oleo Chemicals.

Voting and procedural notes

The Statutory Audit Report for standalone and consolidated statements, along with the Secretarial Audit Report for FY26, contained modified opinions and observations. Management responses to these observations were detailed in the Directors' Report and taken as read during the meeting.

Mr. Mayank Arora, Practicing Company Secretary, served as the scrutinizer for the e-voting process. Members who had not voted remotely were given a 15-minute window to cast their votes after the meeting's conclusion. Results are expected to be declared within two working days.